Skip to main content
Advertisement
Advertisement

CDXS

CDXS logo

Codexis, Inc.

1.37
USD
Sponsored
-0.01
-0.72%
Sep 24, 15:59 UTC -4
Closed
exchange

Pre-Market

1.40

+0.03
+2.48%

CDXS Earnings Reports

Positive Surprise Ratio

CDXS beat 28 of 43 last estimates.

65%

Next Report

Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$18.57M
/
-$0.09
Implied change from Q2 26 (Revenue/ EPS)
+24.48%
/
-30.77%
Implied change from Q3 25 (Revenue/ EPS)
+115.85%
/
-59.09%

Codexis, Inc. earnings per share and revenue

On Aug 11, 2026, CDXS reported earnings of -0.13 USD per share (EPS) for Q2 26, beating the estimate of -0.14 USD, resulting in a 7.67% surprise. Revenue reached 14.91 million, compared to an expected 14.64 million, with a 1.91% difference. The market reacted with a +8.11% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 18.57 million USD, implying an decrease of -30.77% EPS, and increase of 24.48% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
logo
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
logo
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
logo
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
logo
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
logo
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
logo
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
For Q2 2026, Codexis, Inc. reported EPS of -$0.13, beating estimates by 7.67%, and revenue of $14.91M, 1.91% above expectations.
The stock price moved up 8.11%, changed from $1.48 before the earnings release to $1.60 the day after.
The next earning report is scheduled for Nov 04, 2026.
Based on 7 analysts, Codexis, Inc. is expected to report EPS of -$0.09 and revenue of $18.57M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement